Biosimilar Development solution center
-
Taking Charge Of Your Stability Program
10/5/2022
Conducting stability studies is a critical aspect of the drug development process. Learn how consolidating stability testing with a single partner offers improved efficiency, reduced risk, and more.
-
Optimizing Lipid Formulations For Targeted RNA-LNP Applications
9/13/2022
Learn about the considerations and challenges of using ionizable lipids, including the 5 types of lipids used for RNA delivery.
-
Process Development Considerations For RNA-LNP Therapeutics
9/13/2022
Here, we highlight three important process considerations across the RNA-LNP manufacturing workflow which includes limit size behavior, in-line dilution and downstream tangential flow filtration (TFF).
-
Key Stages In mRNA-Based Therapeutic Development
9/13/2022
Learn how planning a product development strategy early on with a technology partner who has deep expertise and technical knowledge of genomic medicines can address uncertainties from the outset.
-
Natural Killer Cells Manufacturing
7/22/2022
Follow the feasibility of xeno‑free NK cell expansion, closure of key unit operations, and how future work could focus on fine‑tuning each step to generate a robust, scalable process.
-
Outstanding Sensitivity For Confident SPR Interaction Analysis
7/20/2022
Explore how surface plasmon resonance (SPR)-based analyses with a high sensitivity instrument can provide greater data precision and better confidence in your results interpretation.
-
Explore Protein Interactions Beyond Affinity To Boost Your Academic Research
7/20/2022
Explore how you can simplify research on protein-protein interactions using our SPR systems.
-
2022 Outsourcing Trends In Biopharmaceutical Manufacturing
6/15/2022
The continued focus on productivity and efficiency is moving manufacturers to increasingly consider outsourcing activities. Biomanufacturers are spending more, demanding better technologies, and expressing greater optimism. This article shares the trends in outsourced activities, percentages of activities outsourced, outsourcing destinations, and offshoring.
-
Leveraging Autoinjector Innovation To De-Risk Biosimilar Development
6/2/2022
Discover how a biopharmaceutical company can de-risk the launch process by choosing a suitable autoinjector technology and partner.
-
Biosimilar Interchangeability: Regulatory & Practical Considerations
3/9/2022
Biosimilar interchangeability refers to the possibility of exchanging the reference biological product with its biosimilar (or vice versa) or exchanging biosimilars of the same reference product. This article provides an up-to-date overview of regulatory and practical considerations regarding biosimilar interchangeability with an emphasis on the European perspective.